Changes in ALBI Score and PIVKA-II within Three Months after Commencing Atezolizumab Plus Bevacizumab Treatment Affect Overall Survival in Patients with Unresectable Hepatocellular Carcinoma

SIMPLE SUMMARY: Atezolizumab plus bevacizumab (Atez/Bev) treatment is now recommended as a first-line systemic treatment for unresectable hepatocellular carcinoma. In this study, we evaluated the therapeutic effects and adverse events of Atez/Bev treatment in the real world including patients with C...

Descripción completa

Detalles Bibliográficos
Autores principales: Unome, Shinji, Imai, Kenji, Takai, Koji, Miwa, Takao, Hanai, Tatsunori, Nishigaki, Yoichi, Hayashi, Hideki, Kochi, Takahiro, Shimizu, Shogo, Nagano, Junji, Iritani, Soichi, Suetsugu, Atsushi, Shimizu, Masahito
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9776967/
https://www.ncbi.nlm.nih.gov/pubmed/36551574
http://dx.doi.org/10.3390/cancers14246089

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9776967/
https://www.ncbi.nlm.nih.gov/pubmed/36551574
http://dx.doi.org/10.3390/cancers14246089

Ejemplares similares